ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Leuprolide

Also written as “Leuprorelin”, “Leuprolide acetate” and “Leuprolide Acetate”.

Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Alzheimer Disease · Endometriosis · Breast Neoplasms, led by 18 companies.

Drug pageLeuprolide: every studyMany companies study it; this page follows only the 38 they lead. All 153 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 23, 201538 company-led studies, 2 open or runningNext primary completion: Aug 30, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only60 open or runningphase 4since Apr 23, 2015Oct 16, 2008none ahead
Abbottits history only50 open or runningphase 3since Feb 20, 2008Mar 20, 2003none ahead
AbbVieits history only30 open or runningphase 4since Jul 9, 2010Apr 24, 2008none ahead
Daewoong Pharmaceuticalits history only31 open or runningphase 4since Jul 3, 2012Jul 3, 2012none ahead
GP-Pharmits history only30 open or runningphase 3since Aug 8, 2005Aug 8, 2005none ahead
Astellas Pharmaits history only20 open or runningphase 4since Jan 25, 2017Sep 19, 2006none ahead
Chong Kun Dang Pharmaceuticalits history only20 open or runningphase 1since May 23, 2016May 23, 2016none ahead
Johnson & Johnsonits history only20 open or runningphase 2since Jun 17, 2009Jun 17, 2009none ahead
Oakwood Laboratoriesits history only20 open or runningphase 3since Jan 26, 2004Jan 26, 2004none ahead
Voyager Pharmaceuticalits history only20 open or runningphase 2since Jun 25, 2003Jun 25, 2003none ahead
Tolmar10 open or runningphase 3since May 5, 2015May 5, 2015none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tolmar only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2015First study: phase 3 study in Puberty, PrecociousFirst studyNCT02452931 · 64 enrolled · United States, Argentina, Canada and more

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

The one study Tolmar leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02452931Puberty, Precocious · United States, Argentina, Canada and more3CompletedSep 5, 201864

How it is read

Names in the registry

  • “Leuprorelin”, 4 entries
  • “Leuprolide acetate”, 4 entries
  • “Leuprolide”, 2 entries
  • “Leuprolide Acetate”, 2 entries
  • “TAP-144-SR(6M)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.